Your browser doesn't support javascript.
loading
Beyond multidrug-resistant tuberculosis in Europe: a TBNET study.
Günther, G; van Leth, F; Altet, N; Dedicoat, M; Duarte, R; Gualano, G; Kunst, H; Muylle, I; Spinu, V; Tiberi, S; Viiklepp, P; Lange, C.
Affiliation
  • Günther G; Division of Clinical Infectious Diseases and German Center for Infection Research Tuberculosis Unit, Research Center Borstel, Borstel, Germany; Department of Medicine, University of Namibia School of Medicine, Windhoek, Namibia.
  • van Leth F; Department of Global Health, Academic Medical Center, University of Amsterdam and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.
  • Altet N; Hospital Universitari Vall d'Hebron, Barcelona, Spain; Investigació i Recerca en Atenció Primària Jordi Gol, Barcelona, Spain.
  • Dedicoat M; Heart of England Foundation Trust, Birmingham, UK.
  • Duarte R; Centro Hospitalar de Vila Nova Gaia/Espinho, Vila Nova Gaia, Portugal; EpiUnit, Institute of Public Health, Medical School Porto University, Porto, Portugal.
  • Gualano G; L Spallanzani National Institute for Infectious Diseases, Rome, Italy.
  • Kunst H; Heart of England Foundation Trust, Birmingham, UK; Queen Mary University, London, UK.
  • Muylle I; St Pieter University Medical Centre, Brussels, Belgium.
  • Spinu V; Marius-Nasta-Institut, Bucharest, Romania.
  • Tiberi S; Azienda Ospedaliera di Valtellina e Valchiavenna E Morelli Hospital, Reference Hospital for MDR and HIV-TB, Sondalo, Italy; Department of Infection, Barts Health NHS Trust, London, UK.
  • Viiklepp P; National Institute for Health Development, Tallinn, Estonia.
  • Lange C; Division of Clinical Infectious Diseases and German Center for Infection Research Tuberculosis Unit, Research Center Borstel, Borstel, Germany; Department of Medicine, University of Namibia School of Medicine, Windhoek, Namibia; Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Int J Tuberc Lung Dis ; 19(12): 1524-7, 2015 Dec.
Article in En | MEDLINE | ID: mdl-26614196
The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe. We evaluated second-line drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrug-resistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone and almost 70% to any second-line injectable drug. Respectively >90% and >80% of the XDR-TB strains tested showed phenotypic resistance to pyrazinamide and ethambutol. Resistance to prothionamide/ethionamide was high in bacilli from pre-XDR-TB patients (43%) and XDR-TB patients (49%).
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Extensively Drug-Resistant Tuberculosis / Mycobacterium tuberculosis / Antitubercular Agents Type of study: Clinical_trials / Risk_factors_studies Limits: Adult / Female / Humans / Male Country/Region as subject: Europa Language: En Journal: Int J Tuberc Lung Dis Year: 2015 Document type: Article Affiliation country: Namibia Country of publication: France
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Extensively Drug-Resistant Tuberculosis / Mycobacterium tuberculosis / Antitubercular Agents Type of study: Clinical_trials / Risk_factors_studies Limits: Adult / Female / Humans / Male Country/Region as subject: Europa Language: En Journal: Int J Tuberc Lung Dis Year: 2015 Document type: Article Affiliation country: Namibia Country of publication: France